Related Experiment Video

Updated: Jul 9, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

[Pharmacogenetics of anti-cancer drugs]

E Gamelin1, M Boisdron-Celle, A Morel

  • 1Laboratoire d'Oncopharmacologie et Pharmacogénétique, Inserm U564, Centre Régional de Lutte Contre le Cancer Paul Papin, 2, rue Moll, F 49933, Angers Cedex 9, France. e.gamelin@unimedia.fr

Annales Pharmaceutiques Francaises
|December 15, 2007
PubMed

Insights

Pharmacogenetics enables personalized chemotherapy by analyzing patient genomes to predict and prevent toxic side-effects from cytotoxic drugs. This approach uses known gene variations to guide treatment, minimizing adverse reactions.

Area of Science:

  • Pharmacogenomics
  • Chemotherapy
  • Drug Metabolism

Context:

  • Cytotoxic drugs used in chemotherapy have narrow therapeutic indices, leading to significant toxic side-effects.
  • Personalized treatment approaches are crucial for optimizing chemotherapy efficacy and patient safety.
  • Advancements in pharmacogenetic analysis, including accessible genomic data and known gene polymorphisms (SNPs), facilitate individualized treatment strategies.

Purpose:

  • To highlight the role of pharmacogenetics in personalizing chemotherapy treatments.
  • To demonstrate how pharmacogenetic analysis can prevent severe toxicities associated with cytotoxic drugs.
  • To emphasize the clinical utility of identifying specific genetic variations for drug safety.

Summary:

  • Pharmacogenetic analysis, utilizing patient genome data from blood samples, identifies genetic variations (SNPs) in drug targets and metabolism enzymes.
  • Confirmed clinical applications include detecting dihydropyrimidine dehydrogenase deficiency and UGT1A1 7/7 genotype for preventing 5-FU and irinotecan toxicities.
  • Deleterious SNPs typically require therapeutic precautions and expert advice rather than drug contraindication.

Impact:

  • Enables the prevention of severe drug-induced toxicities in cancer patients.
  • Facilitates the development of personalized chemotherapy regimens tailored to individual genetic profiles.
  • Enhances the safety and effectiveness of chemotherapy, improving patient outcomes.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...